Health Care Law Today

Artificial intelligence is rapidly reshaping the digital health sector, driving advances in patient engagement, diagnostics, and operational efficiency.

California’s Office of Health Care Affordability is moving beyond broader policy-setting and into direct intervention at the provider level — a shift all hospitals and health systems across the state should take seriously.

The case, United States v. Sorenson, addressed whether a Medicare-registered distributor violated the AKS in making payments to advertising, marketing, and manufacturing companies that worked to sell orthopedic braces to Medicare patients. The court held that such payments were not “referrals” within the meaning of the AKS because the payments were made to entities that were neither physicians in a position to refer their patients nor other decisionmakers in positions to “leverage fluid, informal power and influence” over health care decisions.

On April 17, 2025, the Centers for Medicare and Medicaid Services (CMS) announced another extension of the deadline by which skilled nursing facilities (SNFs) must revalidate their Medicare enrollments.

On April 15, 2025, President Trump signed an executive order (EO) with the aim of reducing the cost of prescription drugs.

Foley & Lardner LLP hosted and participated in a MedTech round table of investors and business leaders, including chief executive officers, partners, directors, innovation leads, investment funds managers and partners, and general counsels. There was collective interest in understanding how these MedTech leaders are adjusting to the changing business and regulatory environment under the second Trump administration.

Choosing where to resolve a health care dispute can be overwhelming at first glance. After all, in addition to determining where a case can be brought in the first place, there is the question of where it should be brought. The answer will vary based on each case’s unique situation. However, there are at least seven factors that should be considered in all cases.

On April 7, 2025, New Mexico Governor Michelle Lujan Grisham signed into law SB-219, the Medical Psilocybin Act (the Act), making New Mexico the third state in the country to create a legal pathway for patients to access psilocybin, a naturally occurring psychedelic compound produced by certain types of mushrooms.

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation involving this class of drugs.